J. Joseph Kim, Ph.D. President, Chief Executive Officer, Director
CEO CORNER
Dr. J. Joseph Kim
J. Joseph Kim, Ph.D. President, Chief Executive Officer, Director
xxx
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial